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The action of a negative allosteric 
modulator at the dopamine D2 
receptor is dependent upon sodium 
ions
Christopher J. Draper-Joyce1, Ravi Kumar Verma3, Mayako Michino3,6, Jeremy Shonberg2, 
Anitha Kopinathan2, Carmen Klein Herenbrink1, Peter J. Scammells2, Ben Capuano2,  
Ara M. Abramyan3, David M. Thal1, Jonathan A. Javitch4,5, Arthur Christopoulos1, Lei Shi3 &  
J. Robert Lane  1
Sodium ions (Na+) allosterically modulate the binding of orthosteric agonists and antagonists to many 
class A G protein-coupled receptors, including the dopamine D2 receptor (D2R). Experimental and 
computational evidences have revealed that this effect is mediated by the binding of Na+ to a conserved 
site located beneath the orthosteric binding site (OBS). SB269652 acts as a negative allosteric 
modulator (NAM) of the D2R that adopts an extended bitopic pose, in which the tetrahydroisoquinoline 
moiety interacts with the OBS and the indole-2-carboxamide moiety occupies a secondary binding 
pocket (SBP). In this study, we find that the presence of a Na+ within the conserved Na+-binding pocket 
is required for the action of SB269652. Using fragments of SB269652 and novel full-length analogues, 
we show that Na+ is required for the high affinity binding of the tetrahydroisoquinoline moiety within 
the OBS, and that the interaction of the indole-2-carboxamide moiety with the SBP determines the 
degree of Na+-sensitivity. Thus, we extend our understanding of the mode of action of this novel class 
of NAM by showing it acts synergistically with Na+ to modulate the binding of orthosteric ligands at 
the D2R, providing opportunities for fine-tuning of modulatory effects in future allosteric drug design 
efforts.
Dopamine receptors (DRs) are class A G-protein coupled receptors (GPCRs) implicated in the biology and treat-
ment of a number of central nervous system disorders1. Drug development at these receptors has focused upon 
targeting the orthosteric site where dopamine binds. However, the advantages of targeting allosteric sites have 
begun to be explored for many GPCRs. This includes the dopamine D2 receptor (D2R), for which drug-like pos-
itive (PAM) and negative (NAM) allosteric modulators have recently been identified2–7. SB269652 (1) is the first 
small molecule NAM of the D2R despite having a structure similar to many competitive antagonists of the D2-like 
DRs5. This structure is comprised of a tetrahydroisoquinoline (THIQ) primary pharmacophore (PP) connected 
by a cyclohexylene linker to a lipophilic 1H-indole-2 carboxamide secondary pharmacophore (SP). Truncated 
derivatives of SB269652 containing the THIQ PP, which is protonated at physiological pH, act in a competitive 
manner with dopamine. Our previous modelling studies predicted that the basic tertiary amine within the THIQ 
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PP of SB269652 forms a salt bridge with Asp3.32 (Ballosteros and Weinstein numbering system)8 in the orthosteric 
binding site (OBS), while the 1H-indole-2-carboxamide SP of SB269652 extends away from the OBS to interact 
with residues in a secondary binding pocket (SBP) between the extracellular ends of transmembrane segments 
(TMs) 2 and 72. To reconcile an orthosteric mode of engagement with an allosteric mechanism of action, we 
proposed that SB269652 acts to engage one protomer of a D2R dimer in a bitopic binding mode to modulate 
dopamine binding and function in the adjacent protomer2.
The modulatory effects of sodium ions (Na+) on orthosteric ligand binding at class A GPCRs has been well 
characterised9–14. Recently, high resolution structures of the adenosine A2A receptor (A2AAR)15 the β1 adrenergic 
receptor16, protease activated receptor17, the δ-opioid receptor18, and the D4R19, revealed a Na+-binding site below 
the orthosteric pocket in which a Na+ is coordinated by the side chain oxygen atoms of Asp2.50, Ser3.39, and three 
water molecules. Molecular dynamics (MD) studies of the A2AAR show that the presence of Na+ in this pocket 
inhibits conformational movement of TM7 toward TM3 at the intracellular side, stabilising an “inactive” confor-
mation. Thus, the absence of Na+ is associated with the active conformation of the receptor, which has a greater 
dynamic flexibility in the movement of Trp6.48 and Asn7.45 20,21.
Physiologically relevant concentrations of Na+ have been shown to decrease agonist affinity for the D2R while 
enhancing the affinity for some classes of antagonists22,23. Substituted benzamides, including eticlopride and 
sulpiride, display increased affinity in the presence of Na+, whereas spiperone is insensitive and the affinity of 
zotepine is decreased24. Substitution of Asp2.50 of the D2R with an uncharged residue reduces the affinity of some 
antagonists11,12. Our previous docking and MD studies provided insight into the mechanism behind the distinct 
Na+ sensitivities of these antagonists, revealing an allosteric interaction network that propagates cooperative 
effects from the Na+ binding site to the OBS24. In particular, Na+ binding stabilised an interaction between the 
side chains of Asp3.32 and Tyr7.43. In the Na+-unbound condition, the less optimal binding modes of the Na+ sen-
sitive antagonists are correlated with the weakening of this hydrogen bond interaction. Another study revealed 
that Na+ binding to this conserved site was important for the subtype selectivity of D4R-selective agonists and 
antagonists through modulation of the interaction of the SP of such ligands to a residue within the SBP25. Using 
MD simulations, Selent and coworkers proposed that Na+ enters the D2R via the extracellular side of the recep-
tor, moving along a network of negatively charged residues including Glu952.65 before entering the Na+-binding 
site coordinated by Asp802.50. This Na+ binding was proposed to lock the rotamer toggle switch Trp3866.48 in the 
inactive state26.
In addition to these effects on orthosteric ligand binding, Na+ ions have been shown to modulate the action 
of BMS986122, a PAM of the µ-opioid receptor, which was shown to exert its effect through disruption of the 
Na+ binding site27. This study, as well as the critical role of Na+ in orthosteric D2R ligand binding, prompted 
us to investigate the role of Na+ in the action of SB269652. Here, we demonstrate that the action of SB269652 is 
exquisitely sensitive to the presence of Na+, so that in the absence of Na+, SB269652 no longer inhibits orthosteric 
ligand binding at the D2R. Using mutagenesis, MD simulations and derivatives of SB269652, we demonstrate that 
a Na+ ion, coordinated by Asp802.50, is required for the high affinity binding of the THIQ PP. Interestingly, the 
particularly high Na+-sensitivity of SB269652, compared to both truncated fragments and structurally similar 
extended derivatives, is determined by the interaction between the 1H-indole-2-carboxamide moiety and the SBP.
Results
The binding of [3H]spiperone is insensitive to Na+. Saturation ligand binding studies were performed 
with the antagonist [3H]spiperone at wild-type (WT), D802.50A and E952.65A c-myc-D2LRs stably expressed in 
membranes of Flp-In CHO cells. These assays were performed in the presence or absence of 100 mM NaCl. In 
the absence of NaCl, we included 100 mM of the organic cation N-methyl-D-glucamine (NMDG) to maintain 
buffer ionic strength28,29. Consistent with previous findings12,28, neither the affinity (Kd) of [3H]spiperone nor 
the number of receptors labelled (Bmax) was significantly altered by the presence (100 mM NaCl, Kd = 0.04 nM, 
Bmax = 237.0 fmol/mg) or absence of Na+ (100 mM NMDG, Kd = 0.05 nM, Bmax = 216.1 fmol/mg) (Table 1, one-
way ANOVA with Tukey’s post-hoc test, PKd = 0.90, PBmax = 0.86). Our previous study revealed that Glu952.65 
within the SBP of the D2R was an important determinant of affinity and cooperativity of SB269652. Mutation of 
either Asp802.50 or Glu952.65 to alanine had no statistically significant effect on [3H]spiperone affinity (Kd = 0.1 nM 
and 0.06 nM, respectively, one-way ANOVA with Tukey’s post-hoc test, PD80A = 0.06, PE95A = 0.67) or number of 
receptors labelled (Bmax = 215.4 fmol/mg and 225.5 fmol/mg, respectively, one-way ANOVA with Tukey’s post-
hoc test, PD80A = 0.86, PE95A = 0.99) (Table 1). Furthermore, in the absence of Na+ neither the affinity nor the 
number of sites labelled were significantly altered at either the D802.50A (Kd = 0.06 nM, Bmax = 192.4 ± 10.7 fmol/
mg, one-way ANOVA with Tukey’s post-hoc test, PKd = 0.86, PBmax = 0.27) or E952.65A (Kd = 0.08 nM, Bmax = 196.6 
fmol/mg, one-way ANOVA with Tukey’s post-hoc test, PKd = 0.86, PBmax = 0.36) mutant.
The insensitivity of [3H]spiperone binding to the presence of Na+ makes this ligand an excellent probe radi-
oligand with which to investigate Na+ sensitivity in the action of other D2R ligands. Consistent with published 
results12,22, in the presence of 100 μM GppNHp, the affinity of the endogenous agonist dopamine (100 mM NaCl, 
Ki = 2.6 μM) was not significantly altered in the absence of Na+ (100 mM NMDG, Ki = 5.1 μM, one-way ANOVA 
with Tukey’s post-hoc test, P = 0.41) or upon mutation of Asp802.50 to alanine (Ki = 2.8 μM, one-way ANOVA 
with Tukey’s post-hoc test, P > 0.99) (Fig. 1, Table 1). Mutation of E952.65 to alanine did not significantly alter 
dopamine affinity either (Ki = 3.1 μM, one-way ANOVA with Tukey’s post-hoc test, P = 0.98) (Table 1).
SB269652 displays no activity in the absence of Na+. In the presence of 100 mM NaCl, increasing 
concentrations of SB269652 caused both an incomplete displacement of [3H]spiperone and modulation of dopa-
mine affinity (Fig. 2B). These data were fit to an allosteric ternary complex model to obtain a value of affinity 
for SB269652 (KB = 355 nM) and cooperativity with dopamine (logα = −0.54 ± 0.02, α = 0.29) and [3H]spiper-
one (logα’ = −0.45 ± 0.08, α’ = 0.35, Fig. 2B). In contrast, in the absence of Na+, SB269652 failed to modulate 
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dopamine affinity or displace [3H]spiperone binding (Fig. 2C, Table 1). Thus, we were unable to detect any evi-
dence of SB269652 binding in the absence of Na+. We extended this study to determine whether this exquisite 
Na+ sensitivity reflects a need for a Na+ ion bound within the conserved Na+-binding pocket by measuring the 
ability of SB269652 to displace [3H]spiperone binding to the D802.50A mutant (Fig. 2D, Table 1), in which the 
conserved Na+ site is disrupted. Similar to our observations in the absence of Na+, SB269652 no longer inhibited 
the binding of [3H]spiperone at this mutant even in the presence of 100 mM NaCl. Thus, SB269652 binding is 
dependent on the presence of a Na+ ion in the conserved Na+-binding pocket coordinated by Asp802.50.
A Na+ ion coordinated by Asp802.50 is important for high affinity binding of the THIQ moi-
ety within the OBS. Our previous studies have shown that the presence of a Na+ in the conserved 
Na+-binding pocket can modulate the affinity of some but not all D2R antagonists24. With the hypothesis that 
WT D802.50A E952.65A
100 mM NaCl 100 mM NMDG 100 mM NaCl 100 mM NMDG 100 mM NaCl 100 mM NMDG
[3H]spiperone
pKd (KD nM) 10.45 ± 0.06 (0.04) 10.31 ± 0.12 (0.05) 9.94 ± 0.11 (0.1) 10.24 ± 0.14 (0.06) 10.21 ± 0.09 (0.06) 10.10 ± 0.03 (0.08)
Bmax fmol/mg 237.0 ± 6.7 216.1 ± 10.8 215.4 ± 7.0 192.4 ± 10.7 225.5 ± 27.2 196.6 ± 8.8
Dopamine pKi (Ki, μM) 5.59 ± 0.06 (2.6) 5.29 ± 0.16 (5.1) 5.58 ± 0.06 (2.6) 5.14 ± 0.16 (7.2) 5.5 ± 0.06 (3.1) 5.34 ± 0.09 (4.6)
MIPS1071 pKi (Ki, μM) 5.90 ± 0.07 (1.3) 4.92 ± 0.07* (12) 5.03 ± 0.07* (9.3) 5.14 ± 0.06* (7.2) 5.90 ± 0.09 (1.3) 5.12 ± 0.23* (7.6)
MIPS1059 pKi (Ki, μM) 6.56 ± 0.06 (0.28) 5.76 ± 0.07* (1.7) 5.82 ± 0.07* (1.5) 5.83 ± 0.07* (1.5) 5.94 ± 0.07* (1.2) 5.32 ± 0.10*# (4.8)
SB269652
pKBa (KB, μM) 6.45 ± 0.09 (0.35) ND ND — 5.65 ± 0.10^ (2.2) ND
logαb (α) −0.48 ± 0.08 (0.33) ND ND — −0.25 ± 0.06^ (0.56) ND
MIPS1726
pKBa (KB, nM) 7.52 ± 0.05 (30.2) 6.40 ± 0.06* (398) 6.50 ± 0.06* (316) — 6.91 ± 0.06* (123) 6.09 ± 0.08*#¶ (812)
logαb (α) −1.90 ± 0.08 (0.01) −2.26 ± 0.39 (0.005) −2.13 ± 0.27 (0.007) — −1.91 ± 0.12 (0.01) −1.89 ± 0.31 (0.01)
MIPS1868
pKBa (KB, nM) 7.00 ± 0.07 (100) 6.20 ± 0.08* (631) 6.20 ± 0.10* (631) 6.33 ± 0.09* (468) 6.67 ± 0.03* (212) 6.21 ± 0.12*# (617)
logαb (α) −1.45 ± 0.12 (0.04) −1.48 ± 0.12 (0.03) −0.62 ± 0.06* (0.23) −0.87 ± 0.12* (0.13) −1.39 ± 0.11 (0.04) −1.24 ± 0.16 (0.06)
Table 1. Binding parameters of orthosteric ligand and SB269652 derivatives at N-terminal c-Myc-tagged 
WT, D802.50A, and E952.65A D2LR constructs stably expressed in Flp-In CHO cell membranes. Data is 
the mean ± SEM of three individual experiments. aEstimate of the negative logarithm of the equilibrium 
dissociation constant. bEstimate of the logarithm of the cooperativity factor between the modulator and [3H]
spiperone. cexperiments perfromed using 0.5 nM [3H]spiperone. *Statistically different from corresponding 
affinity estimate of ligand at WT D2LR in the presence of 100 mM NaCl (p < 0.05, one-way ANOVA, Tukey’s 
post hoc test). ^Statistically different from corresponding affinity estimate of ligand at WT D2LR in the presence 
of 100 mM NaCl (p < 0.05, unpaired, two-tailed Student’s t-test). #Statistically different from corresponding 
affinity estimate of ligand at E952.65A in the presence of 100 mM NaCl (p < 0.05, one-way ANOVA, Tukey’s 
post hoc test). ¶Statistically different from corresponding affinity estimate of ligand at WT in the presence of 
100 mM NMDG (p < 0.05, one-way ANOVA, Tukey’s post hoc test). ND signifies that no inhibition of [3H]
spiperone binding was detected. N/A signifies that the parameter was not calculated. ‘-‘ signifies that no binding 
experiments were performed for that condition.
Figure 1. The affinity of dopamine is not significantly changed in the absence of Na+. Competition binding 
experiments performed using membranes of FlpIn CHO cells stably expressing a human Myc-hD2LR and the 
antagonist [3H]spiperone reveal that in the presence of 100 mM NaCl (closed symbols) the mutations D802.50A 
and E952.65A do not significantly change the affinity of dopamine relative to that at the wild type (WT) receptor. 
In the absence of Na+ (open symbols), whereby 100 mM of the organic cation N-methyl-D-glucamine (NMDG) 
is included in the buffer to maintain ionic strength, no change in dopamine affinity is observed at the WT, 
D802.50A or E952.65A hD2LRs relative to the affinity determined in the presence of Na+.
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the THIQ PP of SB269652 requires Na+ bound in the conserved pocket to bind with high affinity to the OBS, 
we performed competition binding experiments with two orthosteric fragments of SB269652; 2-propyl-1,2,3,4
-tetrahydroisoquinoline-7-carbonitrile (2, MIPS1071) and a more extended fragment N-((trans)-4-(2-(7-cyano-
3,4-dihydroisoquinolin-2(1H)yl)ethyl)cyclohexyl)acetamide (3, MIPS1059). Both MIPS1071 and MIPS1059 have 
previously been shown to behave as competitive antagonists of dopamine in functional assays and acted to com-
pletely displace the binding of [3H]spiperone (Ki = 1.3 μM and 275 nM respectively, Fig. 3)2. MIPS1071 displayed 
a significant loss of affinity both in the absence of Na+ and at the D802.50A mutant receptor (Fig. 3A, Table 1). 
In both cases, MIPS1071 was unable to completely displace the binding of [3H]spiperone at a concentration 
of 100 mM. However, by assuming complete displacement, we could estimate values of affinity in the Na+-free 
condition (pKi = 4.92 ± 0.07, Ki = 12 μM) and at the D802.50A mutant receptor (pKi = 5.03 ± 0.07, Ki = 9.3 μM) 
that correspond to a 9-fold and 7-fold loss in affinity respectively (one-way ANOVA, Tukey’s post-hoc test, P−
Na+ < 0.0001, PD80A < 0.0001). Similarly, MIPS1059 displayed a 6-fold or 5-fold decrease in affinity in the absence 
of Na+ (Ki = 1.7 μM,) or at the D802.50A mutant (Ki = 1.5 μM) respectively (Fig. 3B, Table 1, one-way ANOVA, 
Tukey’s post-hoc test, P−Na+ < 0.0001, PD80A < 0.0001). In both cases, no additional effect of the Na+-free con-
dition was observed at the D802.50A mutant. Thus, the Na+ sensitivity of both orthosteric fragments provides 
evidence that a Na+ ion, coordinated by Asp802.50, is required for the high affinity binding of the THIQ PP of 
SB269652 within the OBS. However, given that in the absence of Na+ or at the D802.50A mutant these orthosteric 
fragments display a maximal 10-fold decrease in affinity, if SB269652 displayed a similar loss of affinity then we 
would still be readily able to detect the activity of SB269652 in our binding studies. Thus, the absence of Na+ must 
either have a greater effect upon SB269652 affinity and/or an additional effect upon SB269652 cooperativity. The 
lack of effect of SB269652 in the absence of Na+ means that it is not possible to distinguish these two possibilities. 
However, SB269652 displays relatively modest affinity for the D2R and weak negative cooperativity, resulting 
in only a small window to detect changes in pharmacology. To address this, we extended our study to extended 
derivatives of SB269652 that display higher affinity and negative cooperativity with dopamine.
A Na+ ion coordinated by Asp802.50 modulates the affinity and cooperativity of high affin-
ity derivatives of SB269652. To understand the effect of Na+ on the affinity and/or cooperativity of an 
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Figure 2. The NAM SB269652 has no effect at the hD2LR in the absence of Na+. (A) SB269652 (1) is comprised 
of a 7-cyano-tetrahydroisoquinoline primary pharmacophore and a indole-2-carboxamide secondary 
pharmacophore (SP) linked by a cyclohexylene spacer. (B) In the presence of 100 mM NaCl, SB269652 acts 
to inhibit the binding of both dopamine and [3H]spiperone in a competition binding assay using membranes 
from FlpIN CHO cells stably expressing the WT hD2LR. These data could be fitted to an allosteric ternary 
complex model to derive a value of affinity for SB269652 and values of cooperativity with both dopamine and 
[3H]spiperone (Table 1). (C) In the absence of sodium ions, but the presence of 100 mM NMDG, no effect 
of SB269652 upon dopamine or [3H]spiperone affinity at the hD2LR is observed. (D) In competition binding 
experiments performed using membranes of FlpIn CHO cells stably expressing a human Myc-hD2LR and the 
antagonist [3H]spiperone reveal that in the presence of 100 mM sodium (closed symbols) SB269652 acts to 
partially displace the radioligand consistent with the action of a negative allosteric modulator (NAM). SB269652 
has no effect in the absence of Na+ (open symbols) or at the D802.50A and E952.65A receptor mutants.
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extended allosteric compound, we used an azaindole derivative (4, MIPS1726) that differs through the incor-
poration of an additional nitrogen at the 6-position of the indole-2-carboxamide SP of SB269652. In our com-
petition binding experiments using 0.15 nM [3H]spiperone, increasing concentrations of MIPS1726 completely 
displaced the radioligand (pKB = 8.01 ± 0.05) most likely reflecting high negative cooperativity. Consistent with 
such a mechanism, in the presence of a higher concentration of [3H]spiperone (0.5 nM, Fig. 4A), MIPS1726 
acted to partially displace the radioligand consistent with an allosteric mode of action. These data could be 
fit to an allosteric ternary complex model to estimate a value of affinity (KB = 30 nM) and negative coopera-
tivity with [3H]spiperone (α = 0.01, Table 1). Unlike the complete loss of detectable action of SB269652 in the 
absence of Na+ or at the D802.50A mutant receptor, MIPS1726 retained NAM activity but displayed a significant 
>10-fold loss in affinity (KB = 398 nM and 316 nM, respectively, one-way ANOVA with Tukey’s post-hoc test 
P−Na+ < 0.0001, PD80A < 0.0001, Table 1) with no change in negative cooperativity. Therefore, the absence of a Na+ 
within the Na+-binding pocket, confers a loss of affinity for this extended allosteric compound but does not affect 
cooperativity.
We then extended our investigation to another higher-affinity allosteric derivative of SB269652, MIPS1868 (5), 
that differs from SB269652 through the substitution of a fluorine at the 7-position of the indole-2-carboxamide SP 
(Fig. 4B). This derivative also displays greater negative cooperativity with [3H]spiperone as compared to SB269652 
(KB = 100 nM, α = 0.04, Table 1). Interestingly, we observed different effects of the Na+-free condition compared 
to the mutation of Asp802.50 on this derivative. At the WT D2R, MIPS1868 displayed a modest 6-fold loss of affin-
ity (one-way ANOVA with Tukey’s post-hoc test, P < 0.002) in the absence of Na+ but no significant change in 
negative cooperativity (one-way ANOVA with Tukey’s post-hoc test, P > 0.99). In contrast, the D802.50A mutation 
caused a similar 6-fold loss in affinity (one-way ANOVA with Tukey’s post-hoc test, P < 0.002) plus a 4-fold loss of 
negative cooperativity (one-way ANOVA with Tukey’s post-hoc test, P < 0.002). Thus, for MIPS1868, this muta-
tion has an additional effect upon cooperativity that cannot be reconciled solely through the role of this residue to 
coordinate a Na+ ion in the Na+-binding pocket. It should be noted that both MIPS1726 and MIPS1868 displayed 
relatively modest losses of affinity (10-fold and 6-fold) in the absence of Na+ as compared to the complete lack of 
activity of SB269652. Therefore SB269652 must display a much greater loss of affinity or cooperativity to explain 
its lack of activity at the D2R in this condition. Indeed, for SB269652 to display no activity up to 30 μM then the 
absence of Na+ must confer a greater than 80-fold loss of affinity.
The absence of Na+ disrupts the binding modes of SB269652 and its derivatives. Our previ-
ous modelling studies predicted that SB269652 binds to the D2R in an extended pose in which the THIQ PP 
occupies the OBS while the 1H-indole-2-carboxamide SP of SB269652 extends away from the OBS to interact 
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Figure 3. Fragments of SB269652 contaiing the THIQ core display competitve pharmacology and lower affinity 
in the absence of an Na+ ion coordinated by D802.50. (A) In the presence of 100 mM NaCl (closed symbols) the 
fragment of SB269652, 2-propyl-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (2, MIPS1071) acts to completely 
displace [3H]spiperone in a competition binding assay using membranes from FlpIN CHO cells stably 
expressing the WT hD2LR. The affinity of MIPS1071 is unchanged at the E952.65A receptor mutant but decreased 
at the D802.50A receptor mutant. In the absence of 100 mM NaCl (100 mM NMDG, open symbols), the affinity 
of MIPS1071 is decreased at the WT D2LR and E952.65A mutant but unchanged at the D802.50A mutant. (B) In 
the presence of 100 mM NaCl (closed symbols) N-((trans)-4-(2-(7-cyano-3,4- dihydroisoquinolin-2(1 H)yl)
ethyl)cyclohexyl)acetamide (3, MIPS1059), a fragment that includes the carboxamide but not the indole moiety 
of SB269652, acts to completely displace [3H]spiperone in a competition binding assay using membranes from 
FlpIN CHO cells stably expressing the WT hD2LR. The affinity of MIPS1059 is decreased at both the E952.65A 
and D802.50A receptor mutants. In the absence of 100 mM NaCl (100 mM NMDG, open symbols), the affinity 
of MIPS1071 is significantly decreased at the WT D2LR and E952.65A mutant but unchanged at the D802.50A 
mutant.
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with residues within the SBP2. In particular, these studies suggested that a hydrogen bond interaction between 
Glu952.65 and the indolic NH is important for the affinity and cooperativity of SB269652. To test how the absence 
of the Na+ bound at the canonical Na+-binding site near Asp802.50 would alter the binding poses of SB269652 and 
its aforementioned derivatives, we carried out comparative MD simulations of SB269652, MIPS1059, MIPS1726, 
and MIPS1868 bound to the D2R. For all these complexes, we simulated both the Na+-bound and Na+-unbound 
conditions (See Methods and Table 2).
For all these compounds, whereas in the Na+-bound conditions the THIQ moiety consistently faces the 
TM4-TM5 interface in the OBS, in the Na+-unbound conditions this moiety has a strong tendency to move 
towards the TM5-TM6 interface and deeper into the OBS (Fig. 5A–D, Supplementary Figures 1 and 2). In 
addition, the salt-bridge interaction between the Asp1143.32 and the protonated amine nitrogen (N1, see 
Supplementary Figure 1) of the ligands is significantly weakened compared to that in the Na+-bound conditions 
(Supplementary Figures 1 and 2). We hypothesised that these changes are responsible for the observed differences 
in the binding affinities of these Na+-sensitive ligands. Indeed, the results of our MM/GBSA calculations of the 
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Figure 4. High affinity Derivatives of SB269652 display lower affinity and cooperatiivty in the absence of 
a sodium ion coordinated by D802.50. (A) In the presence of 100 mM NaCl (closed symbols) the azaindole 
derivative of SB269652, (4, MIPS1726) acted to partially displace 0.5 nM [3H]spiperone in a competition 
binding assay using membranes from FlpIN CHO cells stably expressing the WT hD2LR. These data could be 
fit to an allosteric ternary complex model to derive a value of affinity and cooperativity with [3H]spiperone 
(Table 1). In the presence of Na+, MIPS1726 displayed lower affinity at the E952.65A and D802.50 receptor 
mutants (Table 1). In the absence of Na+ (100 mM NMDG, open symbols) MIPS1726 displayed lower affinity 
at the WT and E952.65A D2LRs but no change in affinity at the D802.50A mutant (Table 1). (B) In the presence of 
100 mM NaCl (closed symbols) the 7-fluoro-indole-2-carboxamide derivative of SB269652 (5, MIPS1868) acted 
to partially displace 0.15 nM [3H]spiperone in a competition binding assay using membranes from FlpIN CHO 
cells stably expressing the WT hD2LR. These data could be fit to an allosteric ternary complex model to derive a 
value of affinity for SB269652 and cooperativity with [3H]spiperone (Table 1). In the presence of Na+, MIPS1868 
displayed lower affinity at the E952.65A receptor mutant but lower affinity and cooperativity at the D802.50 
receptor mutant (Table 1). In the absence of Na+ (100 mM NMDG, open symbols) MIPS1868 displayed lower 
affinity at the WT D2LR but no change in affinity at the E952.65A or D802.50A mutants.
Ligand Na+
Number of 
trajectories
Total Length 
(µs)
SB269652
+ 37 18.0
− 4 9.0
MIPS1059
+ 2 4.8
− 2 4.8
MIPS1726
+ 2 4.2
− 4 6.6
MIPS1868
+ 4 6.0
− 2 4.8
Total 57 58.2
Table 2. Summary of MD simulations of D2R in complex with SB269652 and its derivatives.
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ligand binding energies indicate that SB269652 and its derivatives bind more favourably in the Na+-bound con-
ditions than their corresponding Na+-unbound conditions (Supplementary Figure 3). We were also interested in 
investigating how the Na+-unbound condition would affect the orientation of the SP of SB269652 and derivatives 
within the SBP. We found that the interactions between Glu952.65 and the amide nitrogen (N3) or the nitrogen of 
the aryl moiety (N4) of MIPS1868 and MIPS1726 were consistently maintained in the Na+-unbound condition; 
in comparison, the corresponding interactions were predicted to be much weaker for SB269652 (Supplementary 
Figure 2). This suggests that the modifications to the SP of MIPS1726 and MIPS1868 contribute additional 
interactions within the SBP that confer the higher affinity of these ligands. This in turn may explain why the 
Na+-unbound condition ablates the action of SB269652, whereas the NAM activities of MIPS1726 and MIPS1868 
are still detectable in the absence of Na+.
Na+-binding modulates the interaction of SB269652 derivatives with the SBP. We extended our 
study to further explore how Na+ binding might influence the interaction between the indolic NH of SB269652 
and the SBP residue Glu952.65. Consistent with our previous findings, the affinity of SB269652 (6-fold, Student’s 
two-tailed unpaired t-test, P = 0.004) was decreased at the E952.65A mutant2. As observed at the WT D2R, in the 
absence of Na+, SB269652 was unable to inhibit the binding of [3H]spiperone at the E952.65A mutant (Fig. 2C) 
- thus we could not measure an additional effect of the Na+-free condition. The affinity of the orthosteric frag-
ment MIPS1071 was not changed, as compared to WT, by the mutation E952.65A in the presence or absence of 
Na+ (Table 1, one-way ANOVA with Tukey’s post-hoc test, P+Na+ > 0.99, P−Na+ = 0.55). However, the extended 
fragment MIPS1059 displayed a significant 5-fold affinity reduction at the E952.65A mutant compared to the WT 
in the presence of Na+ (Table 1, one-way ANOVA with Tukey’s post-hoc test, P = 0.0002). This loss of affinity may 
reflect the loss of a hydrogen bond interaction between Glu952.65 and the carboxamide NH of MIPS1059. A signif-
icant 3-fold loss of affinity at the E952.65A mutant was also observed in the absence of Na+ (one-way ANOVA with 
Tukey’s post-hoc test, P = 0.01). Similar to observations at the WT D2R, MIPS1059 displays 5-fold lower affinity 
at the E952.65A mutant in the absence of Na+ compared to the E952.65A mutant in the presence of Na+ (one-way 
ANOVA with Tukeys’s post-hoc test, P = 0.0008).
The extended SB269652 derivative, MIPS1726, displayed a significant 4-fold loss in affinity at the E952.65A 
(KB = 123 nM) mutant compared to WT D2R (one-way ANOVA with Tukey’s post-hoc test, P = 0.0003). The 
absence of Na+ caused a further significant 7-fold decrease in affinity at the E952.65A mutant consistent with these 
Figure 5. The absence of Na+ disrupts the binding modes of SB269652 and its derivatives at D2R. The binding 
modes of ligands at the D2R in the presence (grey) and absence (orange) of the Na+ bound near Asp802.50 
show significant differences. The absence of bound Na+ significantly weakens the ionic interaction between 
the Asp1143.32 and the positively charged N1 atom of SB269652 and its derivatives. The THIQ moiety of these 
ligands shows a common tendency to move towards the TM5-TM6 interface and deeper into the OBS. In the 
absence of Na+, high-affinity ligands (MIPS1726 and MIPS1868) form strong hydrogen bonds with Glu952.65 
(Supplementary Figure 2), in contrast to SB269652.
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effects being additive, similar to our observations with the fragment MIPS1059 (one-way ANOVA with Tukey’s 
post-hoc test, P < 0.0001). The loss of affinity for MIPS1726 at the E952.65A mutant as compared to the WT D2R 
in both the presence and absence of Na+ is consistent with presence of a hydrogen bond interaction between the 
azaindole moiety of MIPS1726 and Glu952.65 in both conditions (Table 1, Fig. 4B). The mutation E952.65A caused 
a modest 2-fold decrease in affinity of the extended SB269652-derivative (one-way ANOVA, Tukey’s post-hoc 
test, P = 0.049), MIPS1868, in the presence of Na+. The Na+-free condition caused a further 3-fold decrease in 
the affinity of MIPS1868 at this mutant (one-way ANOVA, Tukey’s post-hoc test, P = 0.02). However, in contrast 
to the 2-fold difference observed for MIPS1726, comparison of the affinity of MIPS1868 at the WT D2R and the 
E952.65A mutant in the absence of Na+ revealed no significant difference (one-way ANOVA with Tukey’s post-hoc 
test, P > 0.99). Interestingly, results from our MD simulations revealed that the extra nitrogen (N5 atom) or the 
fluoro atom on the SP of MIPS1726 and MIPS1868, respectively, form interactions with the hydroxyl group of 
Tyr341.32 in Na+-bound condition (Supplementary Figure 4). In the absence of Na+, the interaction between 
the fluoro atom of MIPS1868 and Tyr341.32 remained stable, whereas the interaction between the N5 atom of 
MIPS1726 and Tyr341.32 weakens, which suggests that interaction between MIPS1868 and Tyr341.32 is relatively 
strong and may mask the presence and absence of the interactions with Glu952.65.
Finally, it is interesting to note that the observed difference in affinity of MIPS1059, MIPS1726 and MIPS1868 
between the WT and E952.65A mutant was significantly and consistently (2-fold) greater in the presence of Na+ as 
compared to the difference observed in the absence of Na+ (Supplementary Table 1). This suggests that in all cases 
the presence of Na+ has a subtle but significant effect upon modulating the interaction between these SB269652 
derivatives and the SBP.
Discussion
The potentially conserved functional role of Na+ at GPCRs30 prompted us to explore the impact of Na+ binding 
on the pharmacology of SB269652, the first small-molecule NAM identified at the D2R. We found that SB269652 
displayed exquisite sensitivity to Na+, losing its modulatory effect in the absence of this ion. Recent crystallo-
graphic, computational modelling and biochemical efforts have revealed a Na+ binding site beneath the OBS that 
includes a highly conserved aspartate (Asp2.50)15,16, which allowed us to carry out a mechanistic study using both 
mutagenesis and computational approaches.
A recent study demonstrated that a μ opioid receptor PAM, BMS986122, decreased the ability of Na+ ions to 
inhibit agonist binding. This observation can be accommodated within a two-state model, whereby BMS986122 
favours an active receptor conformation with a collapsed Na+-binding pocket27. The action of SB269652 cannot 
be reconciled within such a model because it exerts negative allosteric modulation with respect to both ago-
nist and antagonist binding. Previous studies of the D2R revealed that in the absence of Na+, the competitive 
antagonist raclopride exerted non-competitive effects upon both its own binding and that of the antagonist [3H]
spiperone28,31. These observations were rationalised within a model of a D2R dimer whereby the binding of one 
molecule of raclopride to one protomer of this dimer, exerted negative cooperativity in the binding of another 
molecule to the orthosteric site of the other protomer28. We have previously proposed a novel mechanism of 
action for SB269652, where it binds as a bitopic ligand at one protomer and exerts negative cooperativity for the 
binding and action of dopamine at an adjacent protomer2. However, SB269652 and its derivatives MIPS1726 and 
MIPS1868 all display negative allosteric pharmacology with [3H]spiperone in the presence of Na+ ions. Thus, the 
non-competitive action of these ligands cannot be explained by the mechanism proposed to explain the behav-
iour of [3H]raclopride in the absence of Na+28.
Some classes of D2R antagonists such as substituted benzamides show a significant loss of affinity in the 
Na+-unbound state12. We previously demonstrated that in the Na+-unbound state the weakening of a critical 
hydrogen bond interaction between the Asp3.32 and Tyr7.43 residues, positioned above the Na+-binding site, 
led to non-optimal binding modes for these Na+-sensitive antagonists24. Results from these MD simulations 
were consistent with results from a previous study that demonstrated that mutation of Tyr7.43 to cysteine dra-
matically decreased the affinity of sulpiride (185-fold), while only a subtle loss of affinity was observed for the 
Na+-insensitive N-methyl-spiperone (3-fold)32. Ligands that displayed Na+-insensitivity, such as spiperone, make 
additional contacts within the ligand binding pocket that mask the impact of the absence of bound Na+ 24.
The results of mutagenesis and MD simulations in this study reveal that the Na+ sensitivity of SB269652 can 
be reconciled with a mechanism whereby the occupancy of the OBS by the THIQ moiety is dependent upon Na+. 
Indeed, the two fragments of SB269652 (MIPS1071 and MIPS1059) that contain the THIQ moiety and act as 
competitive antagonists displayed pronounced Na+ sensitivity, akin to that of the substituted benzamides2,23,24. 
This Na+ sensitivity is mediated by the interaction of Na+ with Asp802.50, as mutation of this residue to alanine 
produced an identical effect in either the presence or absence of Na+. Consistent with this hypothesis, the pre-
dominant effect of the Na+-free condition was a decrease in affinity of the high affinity allosteric SB269652 ana-
logues MIPS1726 and MIPS1868.
However, while the lack of effect of SB269652 in the absence of Na+ may reflect a significant decrease in affin-
ity for the OBS, the absence of a Na+ coordinated by Asp802.50 caused a relatively modest decrease in affinity of 
the THIQ-containing fragments MIPS1071 and MIPS1059 (10-fold and 6-fold, respectively). Similarly, the higher 
affinity SB269652 derivatives MIPS1726 and MIPS1868 show 12-fold and 5-fold lower affinities respectively in 
the absence of Na+. In comparison, the lack of activity of SB269652 in the absence of Na+ up to a concentration 
of 30 μM requires a much larger (greater than 80-fold) decrease in affinity. This suggests that the absence of Na+ 
exerts effects of greater magnitude upon SB269652 affinity and/or additional effects such as a decrease in negative 
cooperativity. In agreement with a larger impact upon SB269652 affinity, our MD simulations showed that the 
interactions of Glu952.65 in the SBP with the protonated amide nitrogen and the protonated nitrogen of the aryl 
moiety of MIPS1868 and MIPS1726 were maintained even in the Na+-free condition, whereas the corresponding 
interactions were predicted to be much weaker for SB269652. This suggests that the modifications to the SP of 
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MIPS1726 and MIPS1868 relative to the 1H-indole-2-carboxamide SP of SB269652 contribute additional inter-
actions within the SBP that confer the higher affinities of these two derivatives and may explain why the Na+-free 
condition ablates the action of SB269652, while retaining detectable NAM activities of MIPS1726 and MIPS1868. 
The orthosteric fragments MIPS1071 and MIPS1059 lack this SP. Interestingly, the addition of the indole moiety 
of SB269652 does not confer a gain in affinity relative to MIPS1059. Therefore, one possible explanation for the 
greater effect of the Na+-free condition upon SB269652 as compared to these orthosteric fragments, is that the 
addition of the SP of SB269652 not only confers a relatively weak interaction with Glu952.65 but decreases the 
strength of the interaction with residues within the OBS, together conferring a greater sensitivity to Na+.
It is interesting to note that the observed difference in affinity of MIPS1059, MIPS1726 and MIPS1868 between 
the WT and E952.65A mutant was significantly and consistently (2-fold) greater in the presence of Na+ as compared 
to the difference observed in the absence of Na+ (Supplementary Table 1). Such a difference may reflect a change in 
orientation of these ligands such that the interaction with Glu952.65 has less impact upon ligand affinity, or that Na+ 
within the conserved Na+-binding pocket may modulate the shape of the SBP. Indeed, the presence of Na+ within 
this conserved binding pocket was proposed to modulate the affinity of 1,4-disubstituted piperidines/piperazines 
for the D2R by increasing the accessibility of the aryl substituents with V912.61, a residue within the SBP25. However, 
these data may also be consistent with a transient Na+ binding interaction with E952.65 proposed by Selent and 
coworkers that may in turn modulate the interaction of extended compounds such as SB269652 with the SBP26.
Finally, the D802.50A mutation caused a similar decrease in the affinity of MIPS1726 as observed in the 
Na+-free condition and no change in negative cooperativity was observed. In contrast this mutation caused an 
additional 6-fold decrease in the negative cooperativity of MIPS1868, an effect not observed at the WT D2R in 
the Na+-free condition. This suggests that this residue plays a role in determining the cooperativity of MIPS1868 
that cannot be reconciled simply through its role in coordinating a Na+ ion. These differential effects appear to 
depend on the structure of the aryl amide tail moiety, which differs between MIPS1726 and MIPS1868. Thus, the 
interaction between the aryl amide tail moiety of SB269652 or its derivatives and the SBP is important in deter-
mining not only affinity and the magnitude of negative cooperativity but also the effect of Na+-binding and the 
D802.50A mutation2. We speculate that the absence of the Na+ coordinated by Asp802.50 would alter the position of 
the orthosteric THIQ moiety bound in the OBS, leading to a change in position of the aryl amide moiety within 
the SBS. It is interesting to note that in the absence of Na+, the mutation E952.65A has no additional effect upon the 
affinity of MIPS1868 but caused a 2-fold decrease in the affinity of MIPS1726, an effect that may result from a dis-
tinct orientation of these two ligands within the SBS in the Na+-free condition. Indeed the resulting poses of these 
two ligands from our MD simulations show noticeable differences in the SBS, with the indole ring of MIPS1868 
being positioned more extracellularly than that of MIPS1726 in the Na+-free condition, when they lose the inter-
action with Asp3.32 (Supplementary Figure 4). Furthermore, the interaction between the N5 atom of MIPS1726 
and Tyr341.32 was weakened in the absence of Na+ whereas the interaction of the same residue with fluoro atom of 
MIPS1868 and Tyr341.32 remained stable and may mask the effect of the E952.65A mutation.
To date, investigations into the influence of Na+ upon dopamine receptor function have been limited to effects 
on the affinity and efficacy of competitive orthosteric ligands. Here we reveal profound Na+-sensitivity for the 
action of the NAM, SB269652. This effect is predominantly mediated by a Na+ ion located within the conserved 
Na+-binding site and coordinated by Asp802.50. Our previous studies have proposed a mechanism of action for 
SB269652, whereby it adopts a dual orthosteric/allosteric (bitopic) mode of action at the D2R. This study reveals 
that the bound Na+ is required for the high affinity binding of the THIQ moiety of SB269652 and its analogues 
within the OBS. These observations are consistent with a role for the Na+ in shaping the OBS of the D2R, and in 
particular to orient Asp1143.32 in forming a salt bridge with the protonated tertiary amine of the THIQ moiety as 
has been observed for some, but not all, classes of competitive D2R antagonists. Our study also suggests that the 
complete loss of detectable action of SB269652 in the absence of Na+ reflects a difference in interactions within 
the SBP as compared to structurally similar derivatives. Thus, by revealing a synergistic interaction between Na+ 
and SB269652 to modulate orthosteric ligand binding at the D2R we provide further insight into the binding 
mode and mechanism of this new class of allosteric modulator. This can form the basis for fine-tuning such mod-
ulatory effects in future allosteric drug design efforts at this receptor.
Methods
Materials. Dulbecco’s modified Eagle’s medium, Flp-In CHO cells, and hygromycin B were purchased from 
Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from ThermoTrace (Melbourne, VIC, Australia). 
[3H]spiperone and Ultima Gold scintillation cocktail were from PerkinElmer (Boston, MA). All other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO). All compounds were synthesized as described previously2,3 with the 
exception of MIPS1868 and MIPS1726, which were synthesised as described in supplementary information.
Molecular biology. cDNA in pcDNA3.1+ encoding the long isoform of the wild-type human D2 dopa-
mine receptor (D2LR) was obtained from Missouri University of Science and Technology (http://www.cdna.org/). 
Oligonucleotides were purchased from GeneWorks (Hindmarsh, Australia). An N-terminal c-Myc epitope tag 
(EQKLISEEDL) was introduced to the sequence of the D2LR, and flanking AttB sites were introduced to the WT 
D2LR by overlap extension PCR to allow subcloning into the pDONR201TM vector. The c-Myc–tagged WT D2LR 
receptor construct in pDONR201TM was transferred into the pEF5/frt/V5/dest vector using the LR clonase 
enzyme mix (Invitrogen). Desired mutations were introduced using the Quikchange site-directed mutagenesis 
kit (Agilent). Mutations were confirmed by DNA sequencing (Australian Genome Research Facility, Melbourne, 
Australia). Receptor constructs in pEF5/frt/V5/dest were used to transfect Flp-In CHO cells.
Cell culture and membrane preparation. Flp-In CHO cells (Invitrogen) were transfected with the 
pOG44 vector encoding Flp recombinase and the pDEST vector encoding the wild-type or mutant c-Myc-D2LR 
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at a ratio of 9:1 using polyethylenimine (Polysciences, Warrington, PA) as transfection reagent2. 24 hours after 
transfection the cells were subcultured and the medium was supplemented with 700 μg/ml hygromycin B as selec-
tion agent to obtain cells stably expressing the c-Myc-D2LR. FlpIn CHO cells stably expressing the wild-type or 
mutant c-Myc-D2LR were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum and 200 µg/mL of Hygromycin-B, and maintained at 37 °C in a humidified incubator containing 
5% CO2. When cells were approximately 90% confluent, they were harvested and centrifuged (300 g, 3 min, 4 °C). 
The resulting pellet was resuspended in assay buffer either in the presence (20 mM HEPES, 100 mM NaCl, 6 mM 
MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) or absence (20 mM HEPES, 100 mM NMDG, 6 mM MgCl2, 1 mM 
EGTA, and 1 mM EDTA, pH 7.4) of sodium ions. The centrifugation procedure was repeated. The intact cell pellet 
was then resuspended in assay buffer and homogenized using a Polytron homogenizer for three 10 s intervals on 
the maximum setting, with 30 s periods on ice between each burst. The homogenate volume was brought up to 
30 mL, the sample was centrifuged (350 g, 5 min, 4 °C), the pellet was discarded, and the supernatant was cen-
trifuged at 30 000 g for 1 hr at 4 °C. The resulting pellet was resuspended in 5 mL of assay buffer, and the protein 
content was determined using the bicinchoninic acid assay (BCA assay). The homogenate was then separated into 
500 µl aliquots and stored at −80 °C until it was required for binding assays.
[3H]spiperone binding assay. For saturating binding assays cell membranes (c-Myc-D2L-Flp-In CHO, 
20 µg) were incubated with varying concentrations of [3H]spiperone and 10 µM haloperidol as a non-specific 
control, in binding buffer with (20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 
7.4) or without (20 mM HEPES, 100 mM NMDG, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) sodium 
ions to a final volume of 1 mL and were incubated at 37 °C for 3 h. For competition and interaction binding assays 
cell membranes (c-Myc-D2L-Flp-In CHO, 20 µg) were incubated with varying concentrations of test compound 
in binding buffer with (20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) or 
without (20 mM HEPES, 100 mM NMDG, 6 mM MgCl2, 1 mM EGTA, and 1 mM EDTA, pH 7.4) sodium ions, 
containing 0.15 nM of [3H]spiperone and 100 µM GppNHp to a final volume of 1 mL and were incubated at 37 °C 
for 3 h. Binding was terminated by fast-flow filtration over GF/B membranes using a Brandel harvester followed 
by three washes with ice-cold 0.9% NaCl. Bound radioactivity was measured in a Tri-Carb 2900TR liquid scintil-
lation counter (PerkinElmer).
Data analysis. Competition binding curves between [3H]spiperone and dopamine in the absence and pres-
ence of SB269652 were best fit to a one-site model33:
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where KI is the equilibrium dissociation constant of dopamine.
Competition binding curves between [3H]spiperone and SB269652, MIPS1726, MIPS1217 and MIPS1500 
could be fit to the allosteric ternary complex model using the following equation34:
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Where Y is percentage (vehicle control) binding; [A] and [B] are the concentrations of [3H]spiperone and ligand 
of interest, respectively; KA and KB are the equilibrium dissociation constants of [3H]spiperone and ligand of 
interest, respectively; and α is the cooperativity between the ligand of interest and [3H]spiperone. Values of α > 1 
denote positive cooperativity, values < 1 (but > 0) denote negative cooperativity and values = 1 denote neutral 
cooperativity.
The concentration of ligand that inhibited half of the [3H]spiperone binding (IC50) was determined using the 
following equation:
=
+ −
+ −
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Where Y denotes the percentage specific binding, Top and Bottom denote the maximal and minimal asymptotes, 
respectively, IC50 denotes the X-value when the response is midway between Bottom and Top, and nH denotes the 
Hill slope factor. IC50 values obtained from the inhibition curves were converted to Ki values using the Cheng and 
Prusoff equation35.
Molecular modelling and simulations. The binding mode of SB269652 and its derivatives in the D2R 
were investigated as described in our previous study2. Briefly, to acquire a reference binding mode for the tetrahy-
droisoquinoline (THIQ) core of SB269652 in the high-resolution structure of the D3R (Protein Data Bank code 
3PBL36, THIQ core in the protonated form was first docked into the D3R structure with the induced-fit docking 
(IFD) protocol37 implemented in Schrödinger software (release 2016–1, Schrödinger, LLC: New York, NY), and 
the lowest MM/GBSA energy pose from the largest pose cluster was selected as the reference pose. Assuming 
similar binding modes of the THIQ moiety in the near-identical OBS of the D3R and D2R, the pose from the IFD 
trial with our previous equilibrated D2R model36,38 that is closest to the reference pose in the D3R structure was 
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selected. The full-length SB269652 was then docked into the D2R model by a core-constrained IFD protocol38 
with restraints on the heavy atoms (heavy-atom RMSD deviation <2.0 Å) of the selected pose of the THIQ core. 
Representative poses for the SB269652 derivatives, were acquired similarly by using the core-restrain IFD proto-
col, where restraints were applied on the THIQ core of the full-length SB269652, assuming that the THIQ core 
adopts a similar pose in SB269652 derivatives as well.
MD simulations of the D2R–ligand complexes were performed in the explicit water and 1-palmitoyl-2
-oleoylphosphatidylcholine lipid bilayer solvent environment using Desmond MD system (version 4.5; D. E. Shaw 
Research, New York, NY) with the CHARMM36 protein force field39–41, CHARMM36 lipid force field42, and 
TIP3P water model. The ligand parameters were obtained from the GAAMP server43, with the initial force field 
based on CGenFF assigned by ParamChem44. The system charges were neutralized, and a solvent concentration 
of 150 mM NaCl was added. The average system size is ∼111,300 atoms. Each system was first minimized and 
then equilibrated with restraints on the ligand heavy atoms and protein backbone atoms, followed by an isother-
mal–isobaric simulation at 310 K with all atoms unrestrained, as described previously45–47. For each complex, we 
ran multiple trajectories (Table 2).
MD simulation systems for Na+-unbound conditions were generated by removing Na+ ions from WT trajec-
tories and then re-neutralizing the overall charge of the system by removing appropriate number of Cl− ions in 
the water milieu.
MM/GBSA Energy Calculations. MM/GBSA energy calculations on the D2R WT Na+-bound and 
-unbound conditions were performed using protocol implemented in CHARMM (version 40b2)48 using the 
GBSW implicit solvent model49. For each condition, we extracted frames at 1.2 ns interval from the last 300 ns of 
the MD trajectories.
Data Availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request.
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